SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is a US-based biopharmaceutical company that specializes in developing innovative immunotherapies for immune and autoimmune diseases, focusing on type 1 diabetes with its flagship product, SAB-142. SAB Biotherapeutics, Inc. was founded in 2014 in Sioux Falls, US.

The company is focused on the creation of advanced therapies that address immune disorders. Eddie Sullivan is the CEO and co-founder, with a goal to expand their treatment offerings. In October 2021, SAB Biotherapeutics merged with Big Cypress Acquisition Corp. , valuing the transaction at approximately USD 30 mn.

This merger allowed the company to be publicly listed on Nasdaq under the ticker symbols "SABS" and "SABSW" from October 25, 2021. The company has raised a total of USD 7. 50 mn in funding which includes a Series B round that raised USD 14. 00 mn with investors like Merck & Co.

, Inc. and South Dakota Equity Partners. SAB Biotherapeutics specializes in developing immunotherapies for immune and autoimmune disorders, particularly targeting type 1 diabetes (T1D). The primary product, SAB-142, is designed to alter disease progression by modulating the immune response that damages insulin-producing beta cells in the pancreas.

This innovative platform enhances the production of multi-targeted immunoglobulins without relying on human donors, addressing critical needs in North America, Europe, and parts of Asia for effective diabetes management. In 2023, SAB Biotherapeutics reported revenue of USD 2,238,991 with an EBITDA of USD -34,330,038. The company generates income by establishing partnerships with healthcare providers, engaging in licensing agreements, and implementing market access strategies to distribute its therapies. SAB Biotherapeutics plans to leverage its recent funding to advance its pipeline programs and expand market access.

The company aims to introduce new products focused on treating autoimmune disorders while targeting expansion into markets across Europe and Asia by late 2024. The recent USD 60. 5 mn government awards, alongside USD 27 mn from prior awards, will support these initiatives. The merger with Big Cypress Acquisition Corp.

will also facilitate further growth and development of their immunotherapy strategies.